The inaugural feature, published 19th January, highlights the UK’s fastest-growing private companies developing or selling unique, proprietary technologies, and is backed by Singer Capital Markets, HSBC Innovation Banking and BDO.

An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.

Meet Dr Chris Mathes, CCO, Dr Steve Jenkinson, VP Drug Discovery and Safety Assessment, and Tsutomu Mori at booth 4. We hope to see you at our lunch seminar on Thursday 20th February at 13:00 - 13:00hrs. when we will present 'A Clinically Translatable hiPSC Cardiomyocyte Model for Early Cardiac Risk Assessment'.